Zentiva made 10.4 million euros from sales last year, not taking into account Sicomed's results.
We expect consolidated results of around 100 million euros group-wide for this year," said Mariana Wencz, country manager of Zentiva Romania.
"We launched the Simvacard service on the Romanian market in February last year, which generated 5 million-euro sales, and introduced the Modafen drug on the Romanian market last August, which contributed 2 million euros to the company's sales," Wencs said, adding that "the sales rose also due to the activity of product promoting teams."
Simvastatin is the market leader in its respective sector, according to company estimates.
Zentiva intends to introduce 12 new products in the market this year.
Sicomed posted a 20 percent increase in sales in 2005 vs. 2004, according to its preliminary results.
In September last year, Zentiva completed the takeover of the majority shareholder of Sicomed, investment company Venoma Holdings Ltd., for 102 million dollars (some 85 million euros).
Zentiva later made an offer to buy more Sicomed shares.
The operation enabled it to increase its shares to 75 percent.
SIF Oltenia and SIF Muntenia, minority shareholders in Sicomed, subscribed during the offer.
Investment fund QVT Fund LP, which owns 12.9 percent in Sicomed, and the other minority shareholders kept their stakes.
